Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis
Citation
Battat R, Ma C, Jairath V, Khanna R, Feagan BG. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis. Drug Saf. 2019 May;42(5):617-632. doi: 10.1007/s40264-018-00783-1. PMID: 30830573.
Abstract
Vedolizumab, a humanized monoclonal antibody to the α4β7 integrin, reduces lymphocyte trafficking to the intestine.
Join us at the DDW Tradeshow to explore Alimentiv’s groundbreaking research showcased across six posters and two podium presentations. View our full lineup.